Case Study: Establishing Processes for iPSC-Derived Cell Therapies and Managing the Drug Product Workflow

Time: 2:30 pm
day: Day One


• Achieving and maintaining the most pluripotent state, and reflecting ‘natural’ cell phenotypes upon lineage differentiation
• Scaling up iPSC-derived therapy platforms, outlining the number of batches produced and how to define a batch
• Transferring manufacturing processes from auto to allo, identifying areas of synergy to streamline needs for training, GMP space
• Demonstrating safety and purity of iPSC-derived products for clinical application